+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Carbamazepine Test"

2024-2028 Global Carbamazepine Testing in 90 Countries: Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation - Product Thumbnail Image

2024-2028 Global Carbamazepine Testing in 90 Countries: Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation

  • Report
  • October 2024
  • Global
From
Carbamazepine, Testing in 90 Countries - Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation - Product Thumbnail Image

Carbamazepine, Testing in 90 Countries - Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation

  • Report
  • September 2021
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The Carbamazepine Test is an in vitro diagnostic test used to measure the level of the anticonvulsant drug carbamazepine in a patient's blood. It is used to monitor the effectiveness of the drug in treating epilepsy and other seizure disorders, as well as to detect potential drug toxicity. The test is typically performed in a laboratory setting, using a variety of methods such as enzyme-linked immunosorbent assay (ELISA) or high-performance liquid chromatography (HPLC). The Carbamazepine Test market is a niche segment of the larger in vitro diagnostics industry. It is primarily driven by the need for accurate and reliable testing of carbamazepine levels in patients, as well as the increasing prevalence of epilepsy and other seizure disorders. Some companies in the Carbamazepine Test market include Abbott Laboratories, Siemens Healthineers, Roche Diagnostics, and Thermo Fisher Scientific. Show Less Read more